Chinese pediatric highly active antiretroviral therapy observational cohort: A 1-year analysis of clinical, immunologic, and virologic outcomes

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 5, 2007, Pages 594-598

  Zhang, Fujie ^a   Haberer, Jessica E ^a,b   Zhao, Yan ^a   Dou, Zhihui ^a   Zhao, Hongxin ^c   He, Yun ^d   Cao, Guang Hua ^d  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Division of HIV/AIDS   (China)

Author keywords

Developing world; Highly active antiretroviral therapy; Outcomes; Pediatric

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ANEMIA; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILDHOOD DISEASE; CHINESE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHINA; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 36549074669     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318158c08e     Document Type: Article

References (13)

1. The Joint United Nations Programme on AIDS, World Health Organization. AIDS Epidemic Update: December 2006. Geneva, Switzerland: WHO; 2006.
2. Taha T, Graham S, Kumwenda N, et al. Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics. 2000;106:E77.
3. Bartlett J. Global HIV: antiretroviral therapy scale up and HIV/AIDS care. Medscape, 2006. Available at: http://www.medscape.com/viewarticle/544609. Accessed January 22, 2007.
4. Song R, Jelagat J, Dzombo D, et al. Efficacy of highly active antiretroviral therapy in HIV-1-infected children in Kenya. Pediatrics. 2007;120:E856-E861.
5. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18:1905-1913.
6. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41:100-107.
7. Doerholt K, Duong T, Tookey P, et al, and the Collaborative HIV Paediatric Study (CHIPS). Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J. 2006;25:420-426.
8. Ministry of Health, People's Republic of China; Joint United Nations Programme on HIV/AIDS, World Health Organization. 2005 Update on the HIV/AIDS Epidemic and Response in China. Beijing, China: Chinese Center for Disease Control and Prevention, 2006.
9. Essajee S, Kim M, Gonzalez C, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1 infected children. AIDS. 1999;13:2523-2532.
10. Steele RG, Grauer D. Adherence to antiretroviral therapy for pediatric HIV infection: review of the literature and recommendations for research. Clin Child Fam Psychol Rev. 2003;6:17-30.
11. Machado ES, Lambert JS, Afonso AO, et al. Overview of genotypic and clinical profiles of human immunodeficiency virus type 1-infected children in Rio De Janeiro, Brazil. An Acad Bras Cienc. 2004;76:727-741.
12. Eshleman SH, Krogstad P, Jackson JB, et al. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis. 2001;183:1732-1738.
13. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children. Towards Universal Access. Geneva, Switzerland: WHO; 2006.